205 related articles for article (PubMed ID: 36908264)
21. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
[TBL] [Abstract][Full Text] [Related]
22. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of alectinib versus crizotinib in alk-positive non-small cell lung cancer: An update meta-analysis.
Xiong R; Fu H; Zhang Q; Li W
Pak J Pharm Sci; 2023 Mar; 36(2):365-372. PubMed ID: 37530142
[TBL] [Abstract][Full Text] [Related]
24. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Gadgeel S; Peters S; Mok T; Shaw AT; Kim DW; Ou SI; Pérol M; Wrona A; Novello S; Rosell R; Zeaiter A; Liu T; Nüesch E; Balas B; Camidge DR
Ann Oncol; 2018 Nov; 29(11):2214-2222. PubMed ID: 30215676
[TBL] [Abstract][Full Text] [Related]
25. A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer.
Zhao B; Han Y; Wang Y; Wang Y; Wang Y; Xing H; Dai C; Wang Y; Wang H; Ma W
Pharmacol Res; 2021 Dec; 174():105931. PubMed ID: 34626769
[TBL] [Abstract][Full Text] [Related]
26. Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.
Filetti M; Lombardi P; Falcone R; Giusti R; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
Explor Target Antitumor Ther; 2023; 4(6):1136-1144. PubMed ID: 38213541
[TBL] [Abstract][Full Text] [Related]
27. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
28. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
[TBL] [Abstract][Full Text] [Related]
29. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
Wang M; Slatter S; Sussell J; Lin CW; Ogale S; Datta D; Butte AJ; Bazhenova L; Rudrapatna VA
Target Oncol; 2023 Jul; 18(4):571-583. PubMed ID: 37341856
[TBL] [Abstract][Full Text] [Related]
30. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
[TBL] [Abstract][Full Text] [Related]
31. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.
Yu Y; Zhu F; Zhang W; Lu S
J Clin Med; 2022 May; 11(11):. PubMed ID: 35683354
[TBL] [Abstract][Full Text] [Related]
33. ALK Inhibitors in the Treatment of ALK Positive NSCLC.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Front Oncol; 2018; 8():557. PubMed ID: 30687633
[No Abstract] [Full Text] [Related]
34. Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis.
Wen Y; Jiang T; Wu X; Peng H; Ren S; Zhou C
Ther Adv Med Oncol; 2022; 14():17588359221116607. PubMed ID: 36032351
[TBL] [Abstract][Full Text] [Related]
35. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
36. First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis.
Wu KL; Chen HL; Tsai YM; Lee TH; Chang HM; Tsai YC; Chuang CH; Chang YC; Tu YK; Yang CJ; Hung JY; Chong IW
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640394
[TBL] [Abstract][Full Text] [Related]
37. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
[TBL] [Abstract][Full Text] [Related]
39. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Novello S; Mazières J; Oh IJ; de Castro J; Migliorino MR; Helland Å; Dziadziuszko R; Griesinger F; Kotb A; Zeaiter A; Cardona A; Balas B; Johannsdottir HK; Das-Gupta A; Wolf J
Ann Oncol; 2018 Jun; 29(6):1409-1416. PubMed ID: 29668860
[TBL] [Abstract][Full Text] [Related]
40. Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Lin K; Lin J; Huang Z; Fu J; Yi Q; Cai J; Khan M; Yuan Y; Bu J
Front Pharmacol; 2022; 13():881493. PubMed ID: 35645829
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]